Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2020 Jan;188(2):202-204.
doi: 10.1111/bjh.16259. Epub 2019 Nov 4.

Another disappointment in treating relapsed, refractory high-risk aggressive B-cell lymphomas

Toby A Eyre  1
Affiliations
Comment

Another disappointment in treating relapsed, refractory high-risk aggressive B-cell lymphomas

Toby A Eyre. Br J Haematol. 2020 Jan.
No abstract available

Keywords: diffuse large B cell lymphoma; pixantrone; refractory high-risk aggressive B cell lymphomas.

PubMed Disclaimer

Comment on

References

    1. Budde, L.E., Sehn, L.H., Assouline, S., Flinn, I.W., Isufi, I., Yoon, S.-S., Kim, W.-S., Matasar, M.J., Nastoupil, L.J., Santiago, R., Koh, Y., Hernandez, G., Li, C.-C., Kulkarni, P.R., McCall, B., McClellan, S., Yin, S., Gupta, V., Chu, Y.-W. & Bartlett, N.L. (2018) Mosunetuzumab, a full-length bispecific CD20/CD3 antibody, displays clinical activity in relapsed/refractory B-cell non-Hodgkin lymphoma (NHL): interim safety and efficacy results from a phase 1 study. Blood, 132, 399 LP-399.
    1. Crump, M., Neelapu, S.S., Farooq, U., Van Den Neste, E., Kuruvilla, J., Westin, J., Link, B.K., Hay, A., Cerhan, J.R., Zhu, L., Boussetta, S., Feng, L., Maurer, M.J., Navale, L., Wiezorek, J., Go, W.Y. & Gisselbrecht, C. (2017) Outcomes in refractory diffuse large B-cell lymphoma: Results from the international SCHOLAR-1 study. Blood, 130, 1800-1808.
    1. Dickinson, M.J., Morschhauser, F., Iacoboni, G., Carlo-Stella, C., Offner, F.C., Sureda, A., Salles, G., Martinez, J., Crump, M., Thomas, D.N., Morcos, P.N., Ferlini, C., Broeske, A., Bacac, M., Dimier, N.J., Umaña, P., Moore, T., Weisser, M. & Hutchings, M. (2019) Cd20-tcb (rg6026), a novel “2:1” format t-cell-engaging bispecific antibody, induces complete remissions in relapsed/refractory b-cell non-hodgkin's lymphoma. Hematological Oncology, 37, 92-93.
    1. Eyre, T.A., Linton, K.M., Rohman, P., Kothari, J., Cwynarski, K., Ardeshna, K., Bailey, C., Osborne, W.L., Rowntree, C., Eden, D., Shankara, P., Eyre, D.W., Jasani, P., Chaidos, A., Collins, G.P. & Hatton, C.S. (2016) Results of a multicentre UK-wide retrospective study evaluating the efficacy of pixantrone in relapsed, refractory diffuse large B cell lymphoma. British Journal of Haematology, 173, 896-904.
    1. Goy, A., Ramchandren, R., Ghosh, N., Munoz, J., Morgan, D.S., Dang, N.H., Knapp, M., Delioukina, M., Kingsley, E., Ping, J., Beaupre, D.M., Neuenburg, J.K. & Ruan, J. (2019) Ibrutinib plus lenalidomide and rituximab has promising activity in relapsed/refractory non-germinal center B-cell-like DLBCL. Blood, 134, 1024-1036.

LinkOut - more resources